Brigham and Women's Hospital (BWH) was founded at the end of the 19th century and occupies space adjacent to the Quadrangle of Harvard Medical School. Like Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center (BIDMC), it is a full-service hospital with about 700 beds and a full spectrum of cancer care activities. For more than 35 years, BWH has been a close ally of Dana-Farber Cancer Institute (DFCI) in a number of clinical research endeavors, and, with MGH, is a partner of DFCI in Dana-Farber/Partners Cancer Care. BWH houses all of the licensed beds of DFCI, which no longer maintains a separate in-patient service on Dana-Farber property.

BWH, like MGH, also maintains an active and broad portfolio of cancer research activity.  It is a Harvard center of excellence in cancer imaging, endothelial cell research, brain tumor research, and in viral oncology.  BWH is a national center for research on Epstein-Barr Virus under the direction of Dr. Elliott Kieff, who serves as Deputy Associate Director for Basic Science.  It also operates a special laboratory on its campus (the Channing Laboratory) which houses the activities of a major population sciences-associated cancer research unit, the Nurses Health Study, directed by Dr. Frank Speizer, who serves as Associate Director for Core Facilities.

Aster, Jon C.
Berkowitz, Ross S.
Bertagnolli, Monica M.
Black, Peter McLaren
Buring, Julie
Cramer, Daniel
D'Amico, Anthony
Fletcher, Christopher
Kupper, Thomas S.
Kwiatkowski, David J.
Morton, Cynthia C.

Lissa Olbeter
(617) 525-4304
lobeter@partners.org